Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7382 p11
7 January 2006

This article
Reprint   Photocopy

PDF 80K, Acrobat Reader

Letters

· Influenza pandemic
· Preregistration training
· COX-2s
· CAM
· Controlled drugs
· Medicines use reviews
· Pharmacy practice


Letters to the Editor

Preregistration training

Paying bonuses is not a sensible way to improve preregistration training

From Mr I. F. Cawthorne, MRPharmS

Riaz Firfirey argues that the lump sum paid to community pharmacies for training preregistration pharmacists should be reduced, with a bonus at the end of the year for giving the student a satisfactory report (PJ, 17 December 2005, p752).

In my view the preregistration year is about ensuring the student is a safe and competent practitioner. It is important that preregistration tutors are able to give an impartial verdict on the student’s abilities. By linking a bonus for a satisfactory report it would be difficult to feel confident that students were not being signed off inappropriately merely for the cash; indeed for unscrupulous tutors it would be an incentive for them to sign off sub-standard students.

Recognition also needs giving to the fact that most community pharmacy preregistration grants are used to subsidise the salary of the student. Reducing the grant would lead to a reduction in the trainee’s salary.

There may be tutors who might put more effort into training their students. However, in my experience, the best scenario is an enthusiastic and dynamic trainee, who will inevitably energise and stimulate the whole process.

The vast majority of preregistration trainees are knowledgeable and competent and they put as much into a pharmacy department as they get out. We do need to make sure though that those students who struggle are given the support they need, but providing a bonus only for passing students is not a sensible way to make the system work.

Ian Cawthorne
Chief Pharmacist
Rotherham General Hospital

Send your letter to The Editor

Previous Topic (Influenza pandemic)
Next Topic (COX-2s)

Back to Top


©The Pharmaceutical Journal